Tags

Type your tag names separated by a space and hit enter

The endocannabinoid system as a target for the treatment of neurodegenerative disease.

Abstract

The Cannabis sativa plant has been exploited for medicinal, agricultural and spiritual purposes in diverse cultures over thousands of years. Cannabis has been used recreationally for its psychotropic properties, while effects such as stimulation of appetite, analgesia and anti-emesis have lead to the medicinal application of cannabis. Indeed, reports of medicinal efficacy of cannabis can been traced back as far as 2700 BC, and even at that time reports also suggested a neuroprotective effect of the cultivar. The discovery of the psychoactive component of cannabis resin, Delta(9)-tetrahydrocannabinol (Delta(9)-THC) occurred long before the serendipitous identification of a G-protein coupled receptor at which Delta(9)-THC is active in the brain. The subsequent finding of endogenous cannabinoid compounds, the synthesis of which is directed by neuronal excitability and which in turn served to regulate that excitability, further widened the range of potential drug targets through which the endocannabinoid system can be manipulated. As a result of this, alterations in the endocannabinoid system have been extensively investigated in a range of neurodegenerative disorders. In this review we examine the evidence implicating the endocannabinoid system in the cause, symptomatology or treatment of neurodegenerative disease. We examine data from human patients and compare and contrast this with evidence from animal models of these diseases. On the basis of this evidence we discuss the likely efficacy of endocannabinoid-based therapies in each disease context.

Links

  • PMC Free PDF
  • PMC Free Full Text
  • FREE Publisher Full Text
  • Authors+Show Affiliations

    ,

    Centre for Brain Research and Department of Pharmacology, University of Auckland, Auckland, New Zealand.

    ,

    Source

    British journal of pharmacology 160:3 2010 Jun pg 480-98

    MeSH

    Animals
    Cannabinoid Receptor Modulators
    Cannabinoids
    Disease Models, Animal
    Drug Delivery Systems
    Endocannabinoids
    Humans
    Neurodegenerative Diseases
    Receptors, Cannabinoid

    Pub Type(s)

    Journal Article
    Review

    Language

    eng

    PubMed ID

    20590559

    Citation

    Scotter, Emma L., et al. "The Endocannabinoid System as a Target for the Treatment of Neurodegenerative Disease." British Journal of Pharmacology, vol. 160, no. 3, 2010, pp. 480-98.
    Scotter EL, Abood ME, Glass M. The endocannabinoid system as a target for the treatment of neurodegenerative disease. Br J Pharmacol. 2010;160(3):480-98.
    Scotter, E. L., Abood, M. E., & Glass, M. (2010). The endocannabinoid system as a target for the treatment of neurodegenerative disease. British Journal of Pharmacology, 160(3), pp. 480-98. doi:10.1111/j.1476-5381.2010.00735.x.
    Scotter EL, Abood ME, Glass M. The Endocannabinoid System as a Target for the Treatment of Neurodegenerative Disease. Br J Pharmacol. 2010;160(3):480-98. PubMed PMID: 20590559.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - The endocannabinoid system as a target for the treatment of neurodegenerative disease. AU - Scotter,Emma L, AU - Abood,Mary E, AU - Glass,Michelle, PY - 2010/7/2/entrez PY - 2010/7/2/pubmed PY - 2010/10/15/medline SP - 480 EP - 98 JF - British journal of pharmacology JO - Br. J. Pharmacol. VL - 160 IS - 3 N2 - The Cannabis sativa plant has been exploited for medicinal, agricultural and spiritual purposes in diverse cultures over thousands of years. Cannabis has been used recreationally for its psychotropic properties, while effects such as stimulation of appetite, analgesia and anti-emesis have lead to the medicinal application of cannabis. Indeed, reports of medicinal efficacy of cannabis can been traced back as far as 2700 BC, and even at that time reports also suggested a neuroprotective effect of the cultivar. The discovery of the psychoactive component of cannabis resin, Delta(9)-tetrahydrocannabinol (Delta(9)-THC) occurred long before the serendipitous identification of a G-protein coupled receptor at which Delta(9)-THC is active in the brain. The subsequent finding of endogenous cannabinoid compounds, the synthesis of which is directed by neuronal excitability and which in turn served to regulate that excitability, further widened the range of potential drug targets through which the endocannabinoid system can be manipulated. As a result of this, alterations in the endocannabinoid system have been extensively investigated in a range of neurodegenerative disorders. In this review we examine the evidence implicating the endocannabinoid system in the cause, symptomatology or treatment of neurodegenerative disease. We examine data from human patients and compare and contrast this with evidence from animal models of these diseases. On the basis of this evidence we discuss the likely efficacy of endocannabinoid-based therapies in each disease context. SN - 1476-5381 UR - https://www.unboundmedicine.com/medline/citation/20590559/The_endocannabinoid_system_as_a_target_for_the_treatment_of_neurodegenerative_disease_ L2 - https://doi.org/10.1111/j.1476-5381.2010.00735.x DB - PRIME DP - Unbound Medicine ER -